Rock Health

We support inspiring change-makers in healthcare. W Health Ventures is a Boston-based venture capital firm focused on helping entrepreneurs build the future of healthcare delivery. Founded by serial technology entrepreneur, investor, and philanthropist Sunil Wadhwani, W Health invests in early-stage companies that address critical unmet healthcare needs leveraging technology and AI in the US and India. The W Health team and advisory network comprise seasoned investors, physician leaders, technology experts, and healthcare operators in the US and India. Our Vision The healthcare system is broken across the world. This has created large unmet patient needs. W Health Ventures aims to solve critical challenges faced by people due to lack of access, lack of awareness and poor-quality healthcare. Our Mission To touch 100 million lives through the enterprises we help fund and grow

We are dedicated team of experienced investors who help to enable groundbreaking work by investing in and fostering companies and technologies that advance the future of health. Entrepreneur-friendly strategic investor that speeds access to new healthcare products and services to improve patient care Established by UNC REX Healthcare in 2012 as part of its commitment to innovation Partners with emerging companies throughout North Carolina and the U.S. Leverages the talent and subject matter experts across the UNC REX and UNC Health Care network

Rubicon seeks to both invest and partner to build meaningful businesses that create enduring value by transforming the way people receive healthcare. Rubicon’s approach to investing is guided by a deliberative analytic process building ground-up businesses from scratch, as well as empowering large platform and special opportunity companies. GROUND UPWe partner to create transformational companies because we believe there are better ways to solve today’s healthcare challenges. Our ground up business concepts apply data-driven processes to identify value edge, a form of competitive advantage, and combine with mission driven teams. PLATFORM & SPECIAL OPPORTUNITIESWe partner with exceptional companies that create value by transforming lives. We focus on unique healthcare assets that pioneer healthcare solutions.

Founded in 1986 by the Chan family, Morningside is a technology and life science venture investment firm. With offices in Boston, Shanghai and London, the firm invests globally. The group is managed by investment professionals who are entrepreneurial, have deep industry knowledge and are effective in the local environment in which they operate. In addition to its investment activities, Morningside Ventures is strongly committed to social responsibility.

BrightEdge propels groundbreaking patient-centric solutions by investing in and supporting the most innovative startup companies to advance science, reduce disparities, and promote healthcare sustainability. BrightEdge is the innovation, impact investment, and venture capital arm of the American Cancer Society (ACS). Through our donor-funded ACS Impact Venture Fund (AIVF), we further ACS’s mission by investing in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate our vision of ending cancer as we know it, for everyone. About BrightEdge and The American Cancer Society BrightEdge is helping create a stream of alternate income to sustain the critical work being done across our pillars. Donations to BrightEdge become a sustainable source of financial support to the American Cancer Society, diversifying and modernizing the ACS’s income sources. Investment returns from the AIVF portfolio are both reinvested in AIVF to further support new and existing companies in the portfolio and additional proceeds are used to sustain ACS’s lifesaving programs in research, access, and health equity. BrightEdge investment decisions and innovation programming are guided by the mission priorities of ACS and seek to achieve mission-driven social impact through its proprietary Cancer Impact Investment FrameworkTM (CIIFTM). BrightEdge builds on the American Cancer Society’s commitment to funding and conducting cancer research and plays a key role in accelerating today’s most promising oncology-focused technologies. Our ability to translate scientific discoveries into accessible cures and solutions depends on investments in entrepreneurial for-profit companies that can validate, develop, and commercialize products and services at scale in the healthcare marketplace for people facing cancer. BrightEdge plays a unique role alongside traditional venture capital firms by addressing early-stage funding gaps, incubating high-impact companies, bringing system-level knowledge to companies at critical points in product development, and helping emerging companies access world-class intellectual and human capital as they grow. Learn how BrightEdge will help improve 1.5 million lives by investing in cancer-focused therapies and technologies in its most recent annual report and infographic.

What differentiates Wavemaker 360 the most is the fact that the majority of our investors come from the healthcare industry. We think of them as our company's lifeguards, providing all sorts of support and services to our portfolio companies. Wavemaker 360’s Limited Partners include healthcare corporates, family offices with healthcare backgrounds, and more than 100 individual investors that have spent their career in the healthcare industry. Collectively this group of investors is our secret weapon and superpower - they are willing and able to commercially support the companies we invest into. In fact, for many of them, getting more connectivity to healthcare innovation is a primary reason they are involved with Wavemaker 360. These Limited Partners combine to make Wavemaker 360 the most strategic healthcare-focused venture fund in the US and give the fund an “unfair advantage” when it comes to sourcing high quality investment opportunities, evaluating early-stage companies, and providing commercial support post-investment.